CMPS — COMPASS Pathways plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816590 ·
Last close
$13.64
Market Cap
$1.84B
52W High
$15.40
52W Low
$5.54
ADV30
4,126,663
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -40,427,000 | 91,202,000 | 531,739,000 | 466,010,000 | 205,052,000 |
| Dec 2025 | 0 | — | -58,864,000 | -93,878,000 | 210,349,000 | 149,608,000 | 263,197,000 |
| Sep 2025 | 0 | — | -36,612,000 | -137,717,000 | 255,607,000 | 185,937,000 | 218,016,000 |
| Jun 2025 | 0 | — | -38,646,000 | -38,403,000 | 293,536,000 | 221,881,000 | 130,981,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-159,519,000
Investing CF
$0
Financing CF
$362,807,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.15
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-731,392,000
Inventory
—
Receivables
$15,130,000
ST Investments
—
EBIT TTM
$-176,776,000
Pretax Income TTM
$-181,634,000
Interest Exp TTM
$4,858,000
Analysts
15
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -175,290,000 | -287,862,000 | 210,349,000 | 263,197,000 | — | -157,240,000 |
| Dec 2024 | 0 | -157,108,000 | -155,122,000 | 213,666,000 | 58,971,000 | — | -119,186,000 |
| Dec 2023 | 0 | -124,044,000 | -118,464,000 | 275,987,000 | 50,243,000 | — | -97,376,000 |
| Dec 2022 | 0 | -95,979,000 | -91,505,000 | 197,294,000 | 16,014,000 | — | -105,451,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,977,000
NetIncome TTM
$-54,351,000
OpCashFlow TTM
$0
Assets (Latest)
$213,666,000
Forward EPS
$-1.08
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLPGF | Lakefront Biotherapeutics NV | $1.84B | $28.08 | — |
| GENB | Generate Biomedicines, Inc. | $1.84B | $14.32 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.86B | $2.16 | — |
| GHRS | GH Research PLC | $1.82B | $26.51 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.86B | $19.97 | — |
News headlines (Yahoo Finance, 1h cache)
Cathie Wood Dumps AMD, Doubles Down on Meta Stock
2026-07-10 12:57 · Yahoo
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
2026-07-10 07:02 · Yahoo
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
2026-07-10 06:21 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Thursday
2026-07-09 15:10 · Yahoo
Does COMPASS Pathways (CMPS) Have Upside Left Above Fair Value?
2026-07-09 02:12 · Yahoo
CMPS Stock Climbs After-Hours: Analyst Sees Depression Drug Approval By H1 2027 Or Sooner After Strong Trial Data
2026-07-09 01:28 · Yahoo
COMPASS Pathways (CMPS) Extends COMP360 Phase 3 Case As Valuation Questions Return
2026-07-08 18:22 · Yahoo
Compass Pathways' COMP360 Data Supports FDA Approval Potential, RBC Says
2026-07-08 15:36 · Yahoo
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing
2026-07-07 22:13 · Yahoo
Why Psychedelics-Tied Compass Pathways Reversed Its Premarket Losses
2026-07-07 20:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.